Clinical trials
Adjuvant Therapy clinical trials
Below are recruiting adjuvant therapy clinical trials, each written for real people, not researchers. We’re tracking 215 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07670026RecruitingPhase 2
Stronger treatment after surgery for high-risk glioblastoma
This trial tests a more intense chemotherapy plan for people with glioblastoma who had only partial removal of their tumor or whose tumor grew back quickly. The goal is to see if this approach can improve outcomes.
Hangzhou, ZhejiangAges 18 years+ - NCT05965479RecruitingPhase 2
Blood test to guide extra stomach or esophagus cancer treatment
This trial checks whether a blood test after surgery (ctDNA) can help decide if you should receive additional “adjuvant” treatment for stomach, gastroesophageal junction, or lower esophagus cancer that has HER2-positive tumors. It may help reduce the chance of cancer coming back by tailoring therapy to your risk based on the ctDNA result.
Guildford, SurreyAges 18 years+ - NCT07643623RecruitingPhase 2/Phase 3
Immunotherapy for operable stomach cancer before and after surgery
This trial tests a combination of immunotherapy drugs (sintilimab, chemotherapy, and sometimes ipilimumab) given before surgery to shrink stomach or esophageal junction tumors, then continued after surgery. The goal is to improve survival in patients with resectable (removable) gastric or gastroesophageal junction cancer.
Guangzhou, GuangdongAges 18 years+ - NCT07640048Recruiting
Adjuvant therapy after surgery for high-risk bile duct cancer
This study tests additional treatment given after surgery to remove high-risk intrahepatic cholangiocarcinoma (a type of bile duct cancer). The goal is to reduce the chance the cancer comes back and improve survival in patients whose tumors had concerning features.
BeijingAges 18 years+ - NCT07632118RecruitingPhase 3
Radiation and chemotherapy after pancreatic cancer surgery
This trial tests whether combining radiation therapy with chemotherapy (called the GX regimen) after pancreatic cancer surgery helps prevent cancer from returning in patients with high-risk features. The study aims to see if this combination treatment improves outcomes compared to standard care.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT06693024Recruiting
Neratinib after standard therapy for HER2-positive early breast cancer
This trial is testing whether adding neratinib after standard treatment helps prevent HER2-positive early breast cancer from coming back. It is open only to patients treated at Peking University People's Hospital.
Beijing, Beijing MunicipalityAges Any age - NCT07618078Recruiting
Personalized Cancer Risk Assessment for Nasopharyngeal Cancer
This study helps doctors predict which patients with nasopharyngeal cancer (a cancer of the upper throat) will benefit most from additional chemotherapy after radiation treatment. It uses a special blood test and imaging to create a personalized risk score for each patient.
Beijing, Beijing MunicipalityAges 18–75 - NCT06710665Recruiting
Predicting adjuvant therapy success after esophageal cancer surgery
This trial looks at how well the tumor responded to chemotherapy or radiation before surgery, to see if that can help doctors decide next steps like additional treatment. It may help people with esophageal squamous cell cancer who had the tumor removed completely after initial therapy.
Fuzhou, FujianAges 18 years+ - NCT06609876Recruiting
Donafenib after ablation for recurrent liver cancer
This trial tests whether taking the drug donafenib after a procedure called ablation (which destroys liver tumors) can help keep your liver cancer from returning. It is for people whose liver cancer has come back within the past year and who have small, treatable tumors.
Beijing, None SelectedAges 18–75 - NCT07594964RecruitingPhase 1
Safety Study of XH001 Injection for High-Risk Recurrent Solid Tumors
This early-stage trial tests a new injection called XH001 as an additional treatment after surgery for patients with high-risk cancers that have come back. The goal is to check if it's safe and whether it helps prevent the cancer from returning again.
BeijingAges 18–70 - NCT07590024RecruitingPhase 3
Personalized Cancer Treatment Guidance for Nasopharyngeal Cancer
This trial tests whether a special analysis of blood markers and imaging scans can help doctors choose the best combination of chemotherapy and radiation for nasopharyngeal cancer. The goal is to improve outcomes by tailoring treatment to each patient's specific cancer characteristics.
Beijing, Beijing MunicipalityAges 18–65 - NCT07562503RecruitingPhase 2
Blood Test to Guide Colorectal Cancer Follow-Up Treatment
This trial tests whether a special blood test that detects cancer DNA can help doctors decide if you need additional chemotherapy after colorectal cancer surgery. The goal is to personalize treatment based on your individual risk rather than giving chemotherapy to everyone.
ShanghaiAges 18–80 - NCT07492615RecruitingPhase 2
Sintilimab plus chemo vs. chemo alone for stomach cancer after surgery
This trial tests whether adding the immunotherapy drug Sintilimab to standard chemotherapy after surgery can help prevent stomach or gastroesophageal junction cancer from coming back. It's for people with high-risk or advanced stage cancer that has a specific genetic feature (dMMR or MSI-H).
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07474324RecruitingPhase 2
Targeted therapy plus chemo vs chemo alone for stage 3 stomach cancer
This trial tests adding disitamab vedotin (a drug that targets HER2) to standard chemotherapy (SOX) after surgery for stage 3 stomach cancer. The goal is to see if the combination works better than chemo alone to prevent cancer from coming back.
Nanjing, JiangsuAges 18–75 - NCT06685289RecruitingPhase 2
Donafenib and capecitabine after surgery for biliary cancer with high risk of return
This trial tests whether taking donafenib and capecitabine pills after surgery can help prevent biliary cancer from coming back in people who have a high risk of recurrence. It is for patients whose cancer was completely removed but had certain features that make recurrence more likely.
Nanjing, JiangsuAges 18–75 - NCT07441460RecruitingPhase 3
KN026 plus HB1801 after surgery for HER2-positive breast cancer
This trial tests a combination of two drugs (KN026 and HB1801) given after surgery to prevent breast cancer from coming back in people with HER2-positive breast cancer that had spread to lymph nodes. It aims to improve cure rates with a targeted approach.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07439848RecruitingPhase 1/Phase 2
Stem cells for severe lung injury from sepsis
This trial tests if adding stem cells or their growth liquid to standard sepsis treatment helps adults with severe breathing problems. It may improve recovery for those whose family agrees to the study.
Jakarta Pusat, DKI JakartaAges 40 years+ - NCT07441226RecruitingPhase 2
Stem cells for advanced COPD treatment
This trial tests whether adding umbilical cord stem cells to standard triple therapy can help people with Group E COPD. It aims to see if this approach improves lung function and quality of life.
Jakarta, Jakarta Special Capital RegionAges 40–75 - NCT07424560Recruiting
Bladder Cancer DNA Testing Study
This study looks for specific DNA changes in bladder cancer tumors using a precise test. It aims to better understand the disease and may help guide future treatment choices.
Lanzhou, GansuAges 18 years+ - NCT07353645RecruitingPhase 1/Phase 2
KRAS vaccine for colorectal and pancreatic cancer after surgery
This trial tests a new vaccine that targets KRAS mutations in patients with colorectal or pancreatic cancer after surgery and chemotherapy. The goal is to see if the vaccine can help prevent the cancer from coming back.
Nanjing, JiangsuAges 18–75 - NCT05489289RecruitingPhase 3
AK104 to prevent HCC coming back after surgery
This trial tests whether AK104, taken after liver cancer surgery, can lower the chance that the cancer returns. It is for people with high risk of recurrence but no remaining cancer after surgery.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07263386RecruitingPhase 2
Immunotherapy plus chemo for PD-L1-positive stomach cancer
This trial tests whether adding the immunotherapy drug sintilimab to standard chemotherapy (SOX) after surgery helps prevent stomach cancer from returning. It’s for people whose tumors have a protein called PD-L1 and who had cancer in at least 7 lymph nodes.
Nanjing, JiangsuAges 18–75 - NCT07246278RecruitingPhase 1/Phase 2
Celecoxib for Parkinson's: A new way to treat symptoms
This trial tests if adding celecoxib, an anti-inflammatory drug, to standard Parkinson's treatment can help improve symptoms. If you have Parkinson's disease and are at least 18, this study might be an option for you.
TantaAges 50–80 - NCT07227402RecruitingPhase 3
Study of belzutifan and zanzalintinib for recurrent kidney cancer
This trial tests two new drugs, belzutifan and zanzalintinib, for people with advanced kidney cancer that returned after or within 2 years of finishing an immunotherapy treatment after surgery. You cannot have received any other cancer treatments besides that immunotherapy.
Anchorage, AlaskaAges 18 years+
Hear when a new Adjuvant Therapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for adjuvant therapy?
- Yes. Clin2 currently lists 215 recruiting adjuvant therapy studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a adjuvant therapy trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a adjuvant therapy trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.